<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SIMVASTATIN- simvastatinÂ tablet, film coatedÂ </strong><br>KAISER FOUNDATION HOSPITALS<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use simvastatin tablets USP safely and effectively. See full prescribing information for simvastatin tablets USP.<br><br>SIMVASTATIN tablets USP for oral use<br>Initial U.S. Approval: 1991</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="id_58b782f1-32c5-4910-9672-1c9cb897a4a0"></a><table border="none">
<col width="85.0%">
<col width="15.0%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Dosage and Administration</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Coadministration With Other Drugs (<a href="#i4i_section_id_dab99980-a971-4b26-a1ab-43118a7aa309">2.3</a>)</td>
<td align="left" valign="top">  10/2012</td>
</tr>
<tr>
<td align="left" valign="top">Contraindications (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>)</td>
<td align="center" valign="top">10/2012</td>
</tr>
<tr>
<td align="left" valign="top">Warnings and Precautions</td>
<td align="center" valign="top"></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>)</td>
<td align="center" valign="top">10/2012</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Simvastatin tablets USP are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to:  </p>
<ul>
<li>Reduce the risk of total mortality by reducing CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and reduce the risk of non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and the need for revascularization procedures in patients at high risk of coronary events. (<a href="#i4i_section_id_1533f55a-af18-44c2-b55d-dd7184e6f550">1.1</a>)</li>
<li>Reduce elevated total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, TG and increase HDL-C in patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (heterozygous familial and nonfamilial) and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. (<a href="#i4i_section_id_e29e5361-94ea-43c3-8d5c-9ca47cb76ad9">1.2</a>)</li>
<li>Reduce elevated TG in patients with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. (<a href="#i4i_section_id_e29e5361-94ea-43c3-8d5c-9ca47cb76ad9">1.2</a>)</li>
<li>Reduce total-C and LDL-C in adult patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span>. (<a href="#i4i_section_id_e29e5361-94ea-43c3-8d5c-9ca47cb76ad9">1.2</a>)</li>
<li>Reduce elevated total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span> in boys and postmenarchal girls, 10 to 17 years of age with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> after failing an adequate trial of diet therapy. (<a href="#i4i_section_id_e29e5361-94ea-43c3-8d5c-9ca47cb76ad9">1.2</a>, <a href="#i4i_section_id_ffc76c67-0dbc-4530-a6a6-51a4e5884f86">1.3</a>)</li>
</ul>
<p class="Highlighta">Limitations of Use  </p>
<p class="Highlighta">Simvastatin has not been studied in Fredrickson Types I and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>. (<a href="#i4i_section_id_39cc969a-840f-4a0c-8eb0-43d0841e65c2">1.4</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Dose range is 5 to 40 mg/day. (<a href="#i4i_section_id_f7b8a5ea-d77c-430b-852e-67fae8652a1e">2.1</a>)</li>
<li>Recommended usual starting dose is 10 or 20 mg once a day in the evening. (<a href="#i4i_section_id_f7b8a5ea-d77c-430b-852e-67fae8652a1e">2.1</a>)</li>
<li>Recommended starting dose for patients at high risk of CHD is 40 mg/day. (<a href="#i4i_section_id_f7b8a5ea-d77c-430b-852e-67fae8652a1e">2.1</a>) </li>
<li>Due to the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, use of the 80 mg dose of simvastatin tablets USP should be restricted to patients who have been taking simvastatin, USP 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity. (<a href="#i4i_section_id_942c4380-300b-4060-b4fe-fd3abc1d250d">2.2</a>) </li>
<li>Patients who are currently tolerating the 80 mg dose of simvastatin tablets USP who need to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin, USP should be switched to an alternative statin with less potential for the drug-drug interaction. (<a href="#i4i_section_id_942c4380-300b-4060-b4fe-fd3abc1d250d">2.2</a>) </li>
<li>Due to the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, associated with the 80 mg dose of simvastatin tablets USP, patients unable to achieve their LDL-C goal utilizing the 40 mg dose of simvastatin tablets USP should not be titrated to the 80 mg dose, but should be placed on alternative LDL-C-lowering treatment(s) that provides greater LDL-C lowering. (<a href="#i4i_section_id_942c4380-300b-4060-b4fe-fd3abc1d250d">2.2</a>)</li>
<li>Adolescents (10 to 17 years of age) with HeFH: starting dose is 10 mg/day; maximum recommended dose is 40 mg/day. (<a href="#i4i_section_id_3c571f87-3484-4860-8560-6e4b22866fea">2.5</a>)  </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 5 mg; 10 mg; 20 mg; 40 mg; 80 mg (<a href="#i4i_dosage_form_strength_id_54d709ff-f41a-48fe-9561-b5faf884614a">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Concomitant administration of strong CYP3A4 inhibitors. (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>, <a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>)</li>
<li>Concomitant administration of gemfibrozil, cyclosporine, or danazol. (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>, <a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication. (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>, <a href="#i4i_section_id_d6e179e3-c0e3-4233-9c5f-c9b2f9c32dfc">6.2</a>) </li>
<li>Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels. (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>, <a href="#i4i_section_id_23e33e00-d79a-4121-8637-fde4287bab81">5.2</a>) </li>
<li>Women who are pregnant or may become pregnant. (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>, <a href="#i4i_pregnancy_id_582b44ca-1c11-4305-872a-60e20f694f1b">8.1</a>) </li>
<li>Nursing mothers. (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>, <a href="#i4i_nursing_mothers_id_29445cd0-a29a-4715-8f2c-ab15c3f5682d">8.3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="Bold">Patients should be advised of the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with the 80 mg dose. (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>) </span></li>
<li>Skeletal muscle effects (e.g., <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>): Risks increase with higher doses and concomitant use of certain medicines. Predisposing factors include advanced age (â‰¥ 65), female gender, uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>, <a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>, <a href="#i4i_geriatric_use_id_bc83d7fb-cec3-4856-bad2-4388bdfb7bd8">8.5</a>, <a href="#i4i_section_id_6b215660-a7b5-4c2c-bc56-7349ef0f5732">8.6</a>) </li>
<li>Patients should be advised to report promptly any unexplained and/or persistent <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Simvastatin therapy should be discontinued immediately if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. See Drug Interaction table. (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>)</li>
<li>Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter. (<a href="#i4i_section_id_23e33e00-d79a-4121-8637-fde4287bab81">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence â‰¥ 5%) are: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. (<a href="#i4i_section_id_b535a642-856e-4db0-894e-2d6e8538fd9d">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Drug Interactions Associated With Increased Risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></span> (<a href="#i4i_section_id_dab99980-a971-4b26-a1ab-43118a7aa309">2.3</a>, <a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>, <a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>, <a href="#i4i_section_id_15c84c1d-e705-4981-a677-dd3ee74cb043">7.1</a>, <a href="#i4i_section_id_73b457f5-e133-423d-9254-7b9059ac5f10">7.2</a>, <a href="#i4i_section_id_ceda14ef-02cd-4101-9499-04fc66f38ee2">7.3</a>, <a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>) </p>
<a name="id_8e658061-ed81-4fc9-a28b-0a0f23bd704f"></a><table border="1">
<col width="49.4%">
<col width="50.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Interacting Agents</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Prescribing Recommendations</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone), gemfibrozil, cyclosporine, danazol </td>
<td class="Botrule Rrule" align="left" valign="top">Contraindicated with simvastatin </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Verapamil, diltiazem, dronedarone</td>
<td class="Botrule Rrule" align="left" valign="top">Do not exceed 10 mg simvastatin daily </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Amiodarone, amlodipine, ranolazine</td>
<td class="Botrule Rrule" align="left" valign="top">Do not exceed 20 mg simvastatin daily </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Grapefruit juice </td>
<td class="Botrule Rrule" align="left" valign="top">Avoid  grapefruit juice</td>
</tr>
</tbody>
</table>
<ul><li>Other Lipid-Lowering Medications: Use with other fibrate products or lipid-modifying doses (â‰¥ 1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with simvastatin. (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>, <a href="#i4i_section_id_73b457f5-e133-423d-9254-7b9059ac5f10">7.2</a>, <a href="#i4i_section_id_df3960ee-c284-467b-b648-15d2bdf0db46">7.4</a>)</li></ul>
<ul><li>Coumarin Anticoagulants: Concomitant use with simvastatin prolongs INR. Achieve stable INR prior to starting simvastatin. Monitor INR frequently until stable upon initiation or alteration of simvastatin therapy. (<a href="#i4i_section_id_047e9c11-ca18-48a4-bccf-1a5186bc1a93">7.6</a>) </li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: patients should be started at 5 mg/day and be closely monitored. (<a href="#i4i_section_id_ba553f70-4d45-4827-91e4-2a3806260f5b">2.6</a>, <a href="#i4i_section_id_6b215660-a7b5-4c2c-bc56-7349ef0f5732">8.6</a>)</li></ul></div>
<div><div><div></div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Adolescent Patients With <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> (HeFH)</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Restricted Dosing for 80 mg</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Coadministration With Other Drugs</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Patients With <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Adolescents (10 to 17 Years of Age) With <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Chinese Patients Taking Lipid-Modifying Doses (â‰¥ 1 g/day Niacin) of Niacin-Containing Products</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Liver Dysfunction</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Endocrine Function</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Strong CYP3A4 Inhibitors, Cyclosporine, or Danazol </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Lipid-Lowering Drugs That Can Cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> When Given Alone</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Amiodarone, Dronedarone, Ranolazine, or Calcium Channel Blockers</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Niacin</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Digoxin</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Coumarin Anticoagulants</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Colchicine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Clinical Studies in Adults</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Clinical Studies in Adolescents</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span></a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Liver Enzymes</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Pregnancy </a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Breastfeeding </a></h2>
<h2><a href="#section-16.1" class="toc">Simvastatin Tablets USP 5 mg Label Text</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_893eb777-280f-4388-afe5-18ccd520579f"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin tablets USP can be started simultaneously with diet.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1533f55a-af18-44c2-b55d-dd7184e6f550"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events</h2>
<p class="First">In patients at high risk of coronary events because of existing coronary heart disease, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, peripheral vessel disease, history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or other cerebrovascular disease, simvastatin tablets USP are indicated to:</p>
<ul>
<li>Reduce the risk of total mortality by reducing CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>.</li>
<li>Reduce the risk of non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</li>
<li>Reduce the need for coronary and non-coronary revascularization procedures.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e29e5361-94ea-43c3-8d5c-9ca47cb76ad9"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></h2>
<p class="First">Simvastatin tablets USP are indicated to:</p>
<ul>
<li>Reduce elevated total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (total-C), low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>), and triglycerides (TG), and to increase high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL-C) in patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> (Fredrickson type IIb).</li>
<li>Reduce elevated TG in patients with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> (Fredrickson type IV <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>). </li>
<li>Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>). </li>
<li>Reduce total-C and LDL-C in patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ffc76c67-0dbc-4530-a6a6-51a4e5884f86"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Adolescent Patients With <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> (HeFH)</h2>
<p class="First">Simvastatin tablets USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span> levels in adolescent boys and girls who are at least one year post-<span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span>, 10 to 17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present:</p>
<ol>
<li>LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> remains â‰¥ 190 mg/dL; or</li>
<li>LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> remains â‰¥ 160 mg/dL and</li>
</ol>
<ul>
<li>There is a positive family history of premature cardiovascular disease (CVD) or</li>
<li>Two or more other CVD risk factors are present in the adolescent patient.</li>
</ul>
<p>The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C &lt; 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39cc969a-840f-4a0c-8eb0-43d0841e65c2"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Limitations of Use</h2>
<p class="First">Simvastatin tablets USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> Fredrickson types I and V).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_3cf7bb32-1ac6-4ccc-a23d-c1f96adfcb28"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7b8a5ea-d77c-430b-852e-67fae8652a1e"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First">The usual dosage range is 5 to 40 mg/day. In patients with CHD or at high risk of CHD, simvastatin tablets USP can be started simultaneously with diet. The recommended usual starting dose is 10 or 20 mg once a day in the evening. For patients at high risk for a CHD event due to existing CHD, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, peripheral vessel disease, history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or other cerebrovascular disease, the recommended starting dose is 40 mg/day. Lipid determinations should be performed after 4 weeks of therapy and periodically thereafter.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_942c4380-300b-4060-b4fe-fd3abc1d250d"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Restricted Dosing for 80 mg</h2>
<p class="First">Due to the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, particularly during the first year of treatment, use of the 80 mg dose of simvastatin tablets USP should be restricted to patients who have been taking simvastatin, USP 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity [<span class="Italics">see Warnings and Precautions (</span><span class="Underline"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>Â </span>)]<span class="Italics">. </span></p>
<p>Patients who are currently tolerating the 80 mg dose of simvastatin tablets USP who need to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin, USP should be switched to an alternative statin with less potential for the drug-drug interaction. </p>
<p>Due to the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, associated with the 80 mg dose of simvastatin tablets USP, patients unable to achieve their LDL-C goal utilizing the 40 mg dose of simvastatin tablets USP should not be titrated to the 80 mg dose, but should be placed on alternative LDL-C-lowering treatment(s) that provides greater LDL-C lowering. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dab99980-a971-4b26-a1ab-43118a7aa309"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Coadministration With Other Drugs</h2>
<p class="First"><span class="Italics">Patients taking Verapamil, Diltiazem, or Dronedarone </span></p>
<ul><li>The dose of simvastatin tablets USP should not exceed 10 mg/dayÂ  [<span class="Italics">see Warnings and Precautions (</span><span class="Underline"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>Â </span><span class="Italics">), Drug Interactions (</span><span class="Underline"><a href="#i4i_section_id_ceda14ef-02cd-4101-9499-04fc66f38ee2">7.3</a>Â </span><span class="Italics">), and Clinical Pharmacology (</span><span class="Italics"><span class="Underline"><a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a></span></span>)]<span class="Italics">. </span>
</li></ul>
<p><span class="Italics">Patients taking Amiodarone, Amlodipine or Ranolazine </span></p>
<ul><li>The dose of simvastatin tablets USP should not exceed 20 mg/day [<span class="Italics">see Warnings and Precautions (</span><span class="Underline"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>Â </span><span class="Italics">), Drug Interactions (</span><span class="Underline"><a href="#i4i_section_id_ceda14ef-02cd-4101-9499-04fc66f38ee2">7.3</a>Â </span><span class="Italics">), and Clinical Pharmacology (</span><span class="Underline"><a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>Â </span>)]<span class="Italics">. </span>
</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93c79815-ca93-4328-9c15-37fc44433c78"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Patients With <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></h2>
<p class="First">The recommended dosage is 40 mg/day in the evening [<span class="Italics">see Dosage and Administration, Restricted Dosing for 80 mg (</span><span class="Italics"><span class="Underline"><a href="#i4i_section_id_942c4380-300b-4060-b4fe-fd3abc1d250d">2.2</a></span></span>)]. Simvastatin tablets USP should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c571f87-3484-4860-8560-6e4b22866fea"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Adolescents (10 to 17 Years of Age) With <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span></h2>
<p class="First">The recommended usual starting dose is 10 mg once a day in the evening. The recommended dosing range is 10 to 40 mg/day; the maximum recommended dose is 40 mg/day. Doses should be individualized according to the recommended goal of therapy [<span class="Italics">see NCEP Pediatric Panel Guidelines</span><span class="Sup">1</span><span class="Italics">and Clinical Studies (</span><span class="Underline"><a href="#i4i_section_id_f2cffe38-8f2c-4350-90eb-62ff9ec5a8ac">14.2</a>Â </span>)]. Adjustments should be made at intervals of 4 weeks or more.</p>
<p><span class="Sup">1</span> National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program (NCEP): Highlights of the Report of the Expert Panel  </p>
<p>  on Blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels in Children and Adolescents. Pediatrics. 89(3): 495-501.1992.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba553f70-4d45-4827-91e4-2a3806260f5b"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Because simvastatin tablets USP do not undergo significant renal excretion, modification of dosage should not be necessary in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. However, caution should be exercised when simvastatin tablets USP are administered to patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; such patients should be started at 5 mg/day and be closely monitored [<span class="Italics">see Warnings and Precautions (</span><span class="Underline"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>Â </span><span class="Italics">) and Clinical Pharmacology (</span><span class="Underline"><a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>Â </span>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dfd3a78f-bfca-4fa9-a1d9-8161bcacb073"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Chinese Patients Taking Lipid-Modifying Doses (â‰¥ 1 g/day Niacin) of Niacin-Containing Products</h2>
<p class="First">Because of an increased risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> in Chinese patients taking simvastatin 40 mg coadministered with lipid-modifying doses (â‰¥ 1 g/day niacin) of niacin-containing products, caution should be used when treating Chinese patients with simvastatin doses exceeding 20 mg/day coadministered with lipid-modifying doses of niacin-containing products. Because the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is dose-related, Chinese patients should not receive simvastatin 80 mg coadministered with lipid-modifying doses of niacin-containing products. The cause of the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is not known. It is also unknown if the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with coadministration of simvastatin with lipid-modifying doses of niacin-containing products observed in Chinese patients applies to other Asian patients [<span class="Italics">see Warnings and Precautions (</span><span class="Underline"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>Â </span>)].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_54d709ff-f41a-48fe-9561-b5faf884614a"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>Simvastatin tablets USP, 5 mg are light-yellow, round, convex, film-coated tablets, debossed â€œ7152â€? on one side and â€œTVâ€? on the other side. </li>
<li>Simvastatin tablets USP, 10 mg are light-pink, round, convex, film-coated tablets, debossed â€œ7153â€? on one side and â€œTVâ€? on the other side.</li>
<li>Simvastatin tablets USP, 20 mg are tan, round, convex, film-coated tablets, debossed â€œ7154â€? on one side and â€œTVâ€? on the other side.</li>
<li>Simvastatin tablets USP, 40 mg are red, round, convex, film-coated tablets, debossed â€œ7155â€? on one side and â€œTVâ€? on the other side. </li>
<li>Simvastatin tablets USP, 80 mg are brick-red, capsule-shaped, film-coated tablets, debossed â€œ7156â€? on one side and â€œTVâ€? on the other side. </li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Simvastatin tablets are contraindicated in the following conditions: </p>
<ul>
<li>Concomitant administration of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin and nefazodone)Â  [<span class="Italics">see Warnings and Precautions (</span><span class="Underline">5.1Â </span>)]<span class="Italics">.</span>
</li>
<li>Concomitant administration of gemfibrozil, cyclosporine, or danazol [<span class="Italics">see Warnings and Precautions (</span><span class="Underline">5.1Â </span>)]. </li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication [<span class="Italics">see Adverse Reactions (</span><span class="Underline">6.2Â </span>)].</li>
<li>Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels [<span class="Italics">see Warnings and Precautions (</span><span class="Underline">5.2Â </span>)].</li>
<li>Women who are pregnant or may become pregnant. Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are essential for fetal development. Because HMG-CoA reductase inhibitors (statins) decrease <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, simvastatin tablets may cause fetal harm when administered to a pregnant woman. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. There are no adequate and well-controlled studies of use with simvastatin during pregnancy; however, in rare reports congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, simvastatin revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. <span class="Bold">Simvastatin tablets should be administered to women of childbearing age only when such patients are highly unlikely to conceive.</span> If the patient becomes pregnant while taking this drug, simvastatin tablets should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus [<span class="Italics">see Use in Specific Populations (</span><span class="Underline">8.1Â </span>)].</li>
<li>Nursing mothers. It is not known whether simvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require treatment with simvastatin tablets should not breastfeed their infants [<span class="Italics">see Use in Specific Populations (</span><span class="Underline">8.3Â </span>)].</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_0911ba0e-8b27-42fe-9509-41e083c943d2"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></h2>
<p class="First">Simvastatin occasionally causes <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> manifested as <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> with creatine kinase (CK) above ten times the upper limit of normal (ULN). <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> sometimes takes the form of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with or without <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, and rare fatalities have occurred. The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is increased by high levels of statin activity in plasma. Predisposing factors for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> include advanced age (â‰¥ 65 years), female gender, uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><span class="Bold">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, is dose related. </span>In a clinical trial database in which 41,413 patients were treated with simvastatin, 24,747 (approximately 60%) of whom were enrolled in studies with a median follow-up of at least 4 years, the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> was approximately 0.03% and 0.08% at 20 and 40 mg/day, respectively. The incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with 80 mg (0.61%) was disproportionately higher than that observed at the lower doses. In these trials, patients were carefully monitored and some interacting medicinal products were excluded. </p>
<p>In a clinical trial in which 12,064 patients with a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> were treated with simvastatin (mean follow-up 6.7 years), the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (defined as unexplained <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with a serum creatine kinase [CK] &gt; 10 times upper limit of normal [ULN]) in patients on 80 mg/day was approximately 0.9% compared with 0.02% for patients on 20 mg/day. The incidence of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (defined as <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with a CK &gt; 40 times ULN) in patients on 80 mg/day was approximately 0.4% compared with 0% for patients on 20 mg/day. The incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, was highest during the first year and then notably decreased during the subsequent years of treatment. In this trial, patients were carefully monitored and some interacting medicinal products were excluded. </p>
<p><span class="Bold">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, is greater in patients on simvastatin 80 mg compared with other statin therapies with similar or greater LDL-C-lowering efficacy and compared with lower doses of simvastatin. Therefore, the 80 mg dose of simvastatin should be used only in patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity [<span class="Italics">see Dosage and Administration, Restricted Dosing for 80 mg (</span></span><span class="Underline"><a href="#i4i_section_id_942c4380-300b-4060-b4fe-fd3abc1d250d">2.2</a><span class="Bold">Â </span></span><span class="Bold">)]. If, however, a patient who is currently tolerating the 80 mg dose of simvastatin needs to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin, that patient should be switched to an alternative statin with less potential for the drug-drug interaction. Patients should be advised of the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. If symptoms occur, treatment should be discontinued immediately. </span>[<span class="Italics">See Warnings and Precautions (</span><span class="Underline"><a href="#i4i_section_id_23e33e00-d79a-4121-8637-fde4287bab81">5.2</a>Â </span><span class="Italics">).</span>] </p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (IMNM), an autoimmune <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, associated with statin use. IMNM is characterized by: proximal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> without significant <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>; improvement with immunosuppressive agents. </p>
<p><span class="Bold">All patients starting therapy with simvastatin, or whose dose of simvastatin is being increased, should be advised of the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and told to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if muscle signs and symptoms persist after discontinuing simvastatin. Simvastatin therapy should be discontinued immediately if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected.</span> In most cases, muscle symptoms and CK increases resolved when treatment was promptly discontinued. Periodic CK determinations may be considered in patients starting therapy with simvastatin or whose dose is being increased, but there is no assurance that such monitoring will prevent <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. </p>
<p>Many of the patients who have developed <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> on therapy with simvastatin have had complicated medical histories, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> usually as a consequence of long-standing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Such patients merit closer monitoring. Simvastatin therapy should be discontinued if markedly elevated CPK levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. Simvastatin therapy should also be temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, e.g., <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; major surgery; <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>.  </p>
<p><span class="Italics">Drug Interaction</span></p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased by high levels of statin activity in plasma. Simvastatin is metabolized by the cytochrome P450 isoform 3A4. Certain drugs which inhibit this metabolic pathway can raise the plasma levels of simvastatin and may increase the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, and the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or grapefruit juice [<span class="Italics">see Clinical Pharmacology</span> (<span class="Underline"><a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a></span>)]. Combination of these drugs with simvastatin is contraindicated. If short-term treatment with strong CYP3A4 inhibitors is unavoidable, therapy with simvastatin must be suspended during the course of treatment. [<span class="Italics">See Contraindications (</span><span class="Underline"><a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>Â </span><span class="Italics">) and Drug Interactions (</span><span class="Underline"><a href="#i4i_section_id_15c84c1d-e705-4981-a677-dd3ee74cb043">7.1</a>Â </span><span class="Italics">).</span>] </p>
<p>The combined use of simvastatin with gemfibrozil, cyclosporine, or danazol is contraindicated [<span class="Italics">see Contraindications (</span><span class="Underline"><a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>Â </span><span class="Italics">) and Drug Interactions (</span><span class="Underline"><a href="#i4i_section_id_15c84c1d-e705-4981-a677-dd3ee74cb043">7.1</a>Â </span><span class="Italics"> and </span><span class="Italics"><span class="Underline"><a href="#i4i_section_id_73b457f5-e133-423d-9254-7b9059ac5f10">7.2</a></span></span>)]<span class="Italics">. </span></p>
<p>Caution should be used when prescribing other fibrates with simvastatin, as these agents can cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> when given alone and the risk is increased when they are coadministered [<span class="Italics">see Drug Interactions (</span><span class="Italics"><span class="Underline"><a href="#i4i_section_id_73b457f5-e133-423d-9254-7b9059ac5f10">7.2</a></span></span>)]. </p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with simvastatin coadministered with colchicine, and caution should be exercised when prescribing simvastatin with colchicine [<span class="Italics">see Drug Interactions (</span><span class="Italics"><span class="Underline"><a href="#i4i_section_id_bef07379-4e3c-462c-9cc2-78edde4f5387">7.7</a></span></span>)]. </p>
<p>The benefits of the combined use of simvastatin with the following drugs should be carefully weighed against the potential risks of combinations: other lipid-lowering drugs (other fibrates or â‰¥ 1 g/day of niacin), amiodarone, dronedarone, verapamil, diltiazem, amlodipine, or ranolazine [<span class="Italics">see Drug Interactions (</span><span class="Underline"><a href="#i4i_section_id_ceda14ef-02cd-4101-9499-04fc66f38ee2">7.3</a>Â </span><span class="Italics">) and Â </span><span class="Underline"><span class="Bold"><a href="#id_e5de8236-cf7e-4680-9b8b-ff161820865e">Table 3</a></span>Â </span><span class="Italics"> in Clinical Pharmacology (</span><span class="Underline"><a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>Â </span>)]. </p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been observed with simvastatin coadministered with lipid-modifying doses (â‰¥ 1 g/day niacin) of niacin-containing products. In an ongoing, double-blind, randomized cardiovascular outcomes trial, an independent safety monitoring committee identified that the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is higher in Chinese compared with non-Chinese patients taking simvastatin 40 mg coadministered with lipid-modifying doses of a niacin-containing product. Caution should be used when treating Chinese patients with simvastatin in doses exceeding 20 mg/day coadministered with lipid-modifying doses of niacin-containing products. Because the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is dose-related, Chinese patients should not receive simvastatin 80 mg coadministered with lipid-modifying doses of niacin-containing products. It is unknown if the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with coadministration of simvastatin with lipid-modifying doses of niacin-containing products observed in Chinese patients applies to other Asian patients [<span class="Italics">see Drug Interactions (</span><span class="Italics"><span class="Underline"><a href="#i4i_section_id_df3960ee-c284-467b-b648-15d2bdf0db46">7.4</a></span></span>)]. </p>
<p>Prescribing recommendations for interacting agents are summarized in <span class="Bold"><span class="Underline"><a href="#id_95134a4d-2e40-466e-950c-20cbf73b952b">Table 1</a></span></span> [<span class="Italics">see also Dosage and Administration (</span><span class="Underline"><a href="#i4i_section_id_dab99980-a971-4b26-a1ab-43118a7aa309">2.3</a>Â </span><span class="Italics">), Drug Interactions (</span><span class="Underline"><a href="#i4i_interactions_id_6b635f40-e7e7-4778-8d31-db19f87676ac">7</a>Â </span><span class="Italics">) and Clinical Pharmacology (</span><span class="Underline"><a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>Â </span>)]. </p>
<a name="id_95134a4d-2e40-466e-950c-20cbf73b952b"></a><table border="1" width="419">
<caption><span>TABLE 1: Drug Interactions Associated With Increased Risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></span></caption>
<col width="39.4%">
<col width="60.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Interacting Agents</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Prescribing Recommendations</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<p class="First">Strong CYP3A4 Inhibitors, e.g.,:</p>
<p>      Itraconazole</p>
<p>      Ketoconazole</p>
<p>      Posaconazole</p>
<p>      Voriconazole</p>
<p>      Erythromycin</p>
<p>      Clarithromycin</p>
<p>      Telithromycin</p>
<p>      HIV protease inhibitors</p>
<p>      Boceprevir</p>
<p>      Telaprevir</p>
<p>      Nefazodone</p>
<p>Gemfibrozil</p>
<p>Cyclosporine</p>Danazol</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">Contraindicated with simvastatin</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<p class="First">Verapamil</p>
<p>Diltiazem</p>Dronedarone </td>
<td class="Botrule Lrule Rrule" align="left" valign="top">Do not exceed 10 mg simvastatin daily</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<p class="First">Amiodarone</p>
<p>Amlodipine </p>Ranolazine</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">Do not exceed 20 mg simvastatin daily</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Grapefruit juice</td>
<td class="Botrule Rrule" align="left" valign="top">Avoid grapefruit juice</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23e33e00-d79a-4121-8637-fde4287bab81"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Liver Dysfunction</h2>
<p class="First"><span class="Bold">Persistent increases (to more than 3X the ULN) in serum transaminases have occurred in approximately 1% of patients who received simvastatin in clinical studies.</span> When drug treatment was interrupted or discontinued in these patients, the transaminase levels usually fell slowly to pretreatment levels. The increases were not associated with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other clinical signs or symptoms. There was no evidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p>In the Scandinavian Simvastatin Survival Study (4S) [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_bf34010d-c2f4-42ac-9811-79b82a8a6ba7">14.1</a>)</span>], the number of patients with more than one transaminase elevation to &gt; 3X ULN, over the course of the study, was not significantly different between the simvastatin and placebo groups (14 [0.7%] vs. 12 [0.6%]). Elevated transaminases resulted in the discontinuation of 8 patients from therapy in the simvastatin group (n = 2,221) and 5 in the placebo group (n = 2,223). Of the 1,986 simvastatin treated patients in 4S with normal liver function tests (LFTs) at baseline, 8 (0.4%) developed consecutive LFT elevations to &gt; 3X ULN and/or were discontinued due to transaminase elevations during the 5.4 years (median follow-up) of the study. Among these 8 patients, 5 initially developed these abnormalities within the first year. All of the patients in this study received a starting dose of 20 mg of simvastatin; 37% were titrated to 40 mg.</p>
<p>In 2 controlled clinical studies in 1,105 patients, the 12 month incidence of persistent hepatic transaminase elevation without regard to drug relationship was 0.9% and 2.1% at the 40 and 80 mg dose, respectively. No patients developed persistent liver function abnormalities following the initial 6 months of treatment at a given dose.</p>
<p><span class="Bold">It is recommended that liver function tests be performed before the initiation of treatment, and thereafter when clinically indicated. </span>There have been rare postmarketing reports of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking statins, including simvastatin. If serious <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with clinical symptoms and/or <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs during treatment with simvastatin, promptly interrupt therapy. If an alternate etiology is not found do not restart simvastatin. Note that ALT may emanate from muscle, therefore ALT rising with CK may indicate <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> [<span class="Italics">see Warnings and Precautions (</span><span class="Italics"><span class="Underline"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a></span></span>)].</p>
<p>The drug should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. Active liver diseases or unexplained transaminase elevations are contraindications to the use of simvastatin.</p>
<p>As with other lipid-lowering agents, moderate (less than 3X ULN) elevations of serum transaminases have been reported following therapy with simvastatin. These changes appeared soon after initiation of therapy with simvastatin, were often transient, were not accompanied by any symptoms and did not require interruption of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7e2b7d1-d0b4-4538-9a42-6f04945e23af"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Endocrine Function</h2>
<p class="First">Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including simvastatin. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_bdb8b17b-4468-4fbe-8a2d-35643d248e1f"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b535a642-856e-4db0-894e-2d6e8538fd9d"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. </p>
<p>In the pre-marketing controlled clinical studies and their open extensions (2,423 patients with median duration of follow-up of approximately 18 months), 1.4% of patients were discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were: <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> (0.5%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (0.1%), and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (0.1%). The most commonly reported adverse reactions (incidence â‰¥ 5%) in simvastatin controlled clinical trials were: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infections</span> (9%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (7.4%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (7.3%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (6.6%), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5.4%). </p>
<p><span class="Italics">Scandinavian Simvastatin Survival Study</span></p>
<p>In 4S involving 4,444 (age range 35 to 71 years, 19% women, 100% Caucasians) treated with 20 to 40 mg/day of simvastatin (n = 2,221) or placebo (n = 2,223) over a median of 5.4 years, adverse reactions reported in â‰¥ 2% of patients and at a rate greater than placebo are shown in <span class="Bold"><a href="#id_20a30a97-2bf2-435b-84f0-d7f720887635">TABLE 2</a></span>. </p>
<a name="id_20a30a97-2bf2-435b-84f0-d7f720887635"></a><table border="1" width="435">
<caption><span>TABLE 2: Adverse Reactions Reported Regardless of Causality by â‰¥ 2% of Patients Treated With Simvastatin and Greater Than Placebo in 4S</span></caption>
<col width="47.1%">
<col width="29.4%">
<col width="23.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">Simvastatin <br>(N = 2,221) <br>%</td>
<td class="Botrule Rrule" align="center" valign="middle">Placebo <br>(N = 2,223) <br>%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Italics">Body as a Whole</span></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></td>
<td align="center" valign="middle">2.7</td>
<td class="Rrule" align="center" valign="middle">2.3</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center" valign="middle">5.9</td>
<td class="Rrule" align="center" valign="middle">5.8</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Italics">Cardiovascular System Disorders</span></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span></td>
<td align="center" valign="middle">5.7</td>
<td class="Rrule" align="center" valign="middle">5.1</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle"><span class="Italics">Digestive System Disorders</span></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center" valign="middle">2.2</td>
<td class="Rrule" align="center" valign="middle">1.6</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span></td>
<td align="center" valign="middle">4.9</td>
<td class="Rrule" align="center" valign="middle">3.9</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle"><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus</td>
<td align="center" valign="middle">4.2</td>
<td class="Rrule" align="center" valign="middle">3.6</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span></span></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center" valign="middle">3.7</td>
<td class="Rrule" align="center" valign="middle">3.2</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Italics">Nervous System/Psychiatric Disorders</span></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="middle">2.5</td>
<td class="Rrule" align="center" valign="middle">2.1</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" valign="middle">4</td>
<td class="Rrule" align="center" valign="middle">3.8</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td align="center" valign="middle">4.5</td>
<td class="Rrule" align="center" valign="middle">4.2</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td align="center" valign="middle">6.6</td>
<td class="Rrule" align="center" valign="middle">6.3</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center" valign="middle">2.3</td>
<td class="Rrule" align="center" valign="middle">1.8</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle"><span class="Italics">Skin/Skin Appendage Disorders</span></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span></td>
<td align="center" valign="middle">4.5</td>
<td class="Rrule" align="center" valign="middle">3</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle"><span class="Italics">Urogenital System Disorders</span></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>, urinary tract</td>
<td align="center" valign="middle">3.2</td>
<td class="Botrule Rrule" align="center" valign="middle">3.1</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Heart Protection Study </span></p>
<p>In the Heart Protection Study (HPS), involving 20,536 patients (age range 40 to 80 years, 25% women, 97% Caucasians, 3% other races) treated with simvastatin 40 mg/day (n = 10,269) or placebo (n = 10,267) over a mean of 5 years, only serious adverse reactions and discontinuations due to any adverse reactions were recorded. Discontinuation rates due to adverse reactions were 4.8% in patients treated with simvastatin compared with 5.1% in patients treated with placebo. The incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> was &lt; 0.1% in patients treated with simvastatin.</p>
<p><span class="Italics">Other Clinical Studies </span></p>
<p>In a clinical trial in which 12,064 patients with a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> were treated with simvastatin (mean follow-up 6.7 years), the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (defined as unexplained <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with a serum creatine kinase [CK] &gt; 10 times upper limit of normal [ULN]) in patients on 80 mg/day was approximately 0.9% compared with 0.02% for patients on 20 mg/day. The incidence of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (defined as <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with a CK &gt; 40 times ULN) in patients on 80 mg/day was approximately 0.4% compared with 0% for patients on 20 mg/day. The incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, was highest during the first year and then notably decreased during the subsequent years of treatment. In this trial, patients were carefully monitored and some interacting medicinal products were excluded. </p>
<p>Other adverse reactions reported in clinical trials were: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>.</p>
<p><span class="Italics">Laboratory Tests</span></p>
<p>Marked persistent increases of hepatic transaminases have been noted [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_23e33e00-d79a-4121-8637-fde4287bab81">5.2</a>)</span>]. Elevated alkaline phosphatase and Î³-glutamyl transpeptidase have also been reported. About 5% of patients had elevations of CK levels of 3 or more times the normal value on one or more occasions. This was attributable to the noncardiac fraction of CK [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>)</span>].</p>
<p><span class="Italics">Adolescent Patients (Ages 10 to 17 Years)</span></p>
<p>In a 48 week, controlled study in adolescent boys and girls who were at least 1 year post-<span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span>, 10 to 17 years of age (43.4% female, 97.7% Caucasians, 1.7% Hispanics, 0.6% Multiracial) with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (n = 175), treated with placebo or simvastatin (10 to 40 mg daily), the most common adverse reactions observed in both groups were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pediatric_use_id_f6194ef1-7ab9-4f4a-9fe2-36e3b9632851">8.4</a>) and Clinical Studies (<a href="#i4i_section_id_f2cffe38-8f2c-4350-90eb-62ff9ec5a8ac">14.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6e179e3-c0e3-4233-9c5f-c9b2f9c32dfc"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">Because the below reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following additional adverse reactions have been identified during postapproval use of simvastatin: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, a variety of skin changes (e.g., <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, discoloration, dryness of skin/mucous membranes, changes to hair/nails), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>/<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. </p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with statin use [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>)].</p>
<p>An apparent <span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">hypersensitivity syndrome</span> has been reported rarely which has included some of the following features: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, lupus erythematous-like syndrome, <span class="product-label-link" type="condition" conceptid="255348" conceptname="Polymyalgia rheumatica">polymyalgia rheumatica</span>, <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, positive ANA, ESR increase, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
<p>There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (e.g., <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_6b635f40-e7e7-4778-8d31-db19f87676ac"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_15c84c1d-e705-4981-a677-dd3ee74cb043"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Strong CYP3A4 Inhibitors, Cyclosporine, or Danazol </h2>
<p class="First">Strong CYP3A4 inhibitors: Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4. Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  </p>
<p>Elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, particularly with higher doses of simvastatin. <span class="Italics">[See Warnings and Precautions (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>).] </span>Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated <span class="Italics">[see Contraindications (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>)]. </span>If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment. </p>
<p>Cyclosporine or Danazol: The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased by concomitant administration of cyclosporine or danazol. Therefore, concomitant use of these drugs is contraindicated. [<span class="Italics">See Contraindications</span> (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>) ,<span class="Italics">Warnings and Precuations</span> (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>), <span class="Italics">and Clinical Pharmacology</span> (<a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_73b457f5-e133-423d-9254-7b9059ac5f10"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Lipid-Lowering Drugs That Can Cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> When Given Alone</h2>
<p class="First">Gemfibrozil: Contraindicated with simvastatin [<span class="Italics">see Contraindications (</span><span class="Underline"><a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>Â </span><span class="Italics">) and Warnings and Precautions (</span><span class="Italics"><span class="Underline"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a></span></span>)]<span class="Italics">. </span></p>
<p>Other fibrates: Caution should be used when prescribing with simvastatin [<span class="Italics">see Warnings and Precautions (</span><span class="Underline"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>Â </span>)]<span class="Italics">. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ceda14ef-02cd-4101-9499-04fc66f38ee2"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Amiodarone, Dronedarone, Ranolazine, or Calcium Channel Blockers</h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, is increased by concomitant administration of amiodarone, dronedarone,  ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine [<span class="Italics">see Dosage and Administration (</span><span class="Underline"><a href="#i4i_section_id_dab99980-a971-4b26-a1ab-43118a7aa309">2.3</a>Â </span><span class="Italics">) and Warnings and Precautions (</span><span class="Underline"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>Â </span><span class="Italics">), and Â </span><span class="Underline"><span class="Bold"><a href="#id_e5de8236-cf7e-4680-9b8b-ff161820865e">Table 3</a></span>Â </span><span class="Italics"> in Clinical Pharmacology (</span><span class="Italics"><span class="Underline"><a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a></span></span>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df3960ee-c284-467b-b648-15d2bdf0db46"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Niacin</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been observed with simvastatin coadministered with lipid-modifying doses (â‰¥ 1 g/day niacin) of niacin-containing products. In particular, caution should be used when treating Chinese patients with simvastatin doses exceeding 20 mg/day coadministered with lipid-modifying doses of niacin-containing products. Because the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is dose-related, Chinese patients should not receive simvastatin 80 mg coadministered with lipid-modifying doses of niacin-containing products [<span class="Italics">see Warnings and Precautions (</span><span class="Underline"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>Â </span><span class="Italics">) and Clinical Pharmacology (</span><span class="Underline"><a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>Â </span>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_547a6d59-a75e-4742-b6a4-3470421946f6"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Digoxin</h2>
<p class="First">In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma. Patients taking digoxin should be monitored appropriately when simvastatin is initiated [<span class="Italics">see Clinical Pharmacology (</span><span class="Underline"><a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>Â </span>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_047e9c11-ca18-48a4-bccf-1a5186bc1a93"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Coumarin Anticoagulants</h2>
<p class="First">In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20 to 40 mg/day modestly potentiated the effect of coumarin anticoagulants: the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively. With other statins, clinically evident <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time has been reported in a few patients taking coumarin anticoagulants concomitantly. In such patients, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time occurs. Once a stable <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time has been documented, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of simvastatin is changed or discontinued, the same procedure should be repeated. Simvastatin therapy has not been associated with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or with changes in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients not taking anticoagulants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bef07379-4e3c-462c-9cc2-78edde4f5387"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Colchicine</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with simvastatin coadministered with colchicine, and caution should be exercised when prescribing simvastatin with colchicine. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_fdb8fcc2-416d-4ec0-981c-e7a32a06d937"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_582b44ca-1c11-4305-872a-60e20f694f1b"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_bbbfcef0-3753-42de-996e-c2404af03574"></a><a name="section-8.1.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_X_id_9237a8b7-db87-4f38-911d-60a23934c27a"></a><a name="section-8.1.1.1"></a><p></p>
<h4>Pregnancy Category X </h4>
<p class="First">[ <span class="Italics">See Contraindications</span> (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>)].</p>
<p>Simvastatin is contraindicated in women who are or may become pregnant. Lipid lowering drugs offer no benefit during pregnancy, because <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are needed for normal fetal development. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> therapy. There are no adequate and well-controlled studies of use with simvastatin during pregnancy; however, there are rare reports of congenital anomalies in infants exposed to statins <span class="Italics">in utero</span>. Animal reproduction studies of simvastatin in rats and rabbits showed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are essential for fetal development. Because statins decrease <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, simvastatin may cause fetal harm when administered to a pregnant woman. If simvastatin is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. </p>
<p>There are rare reports of congenital anomalies following intrauterine exposure to statins. In a review<span class="Sup">2</span> of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or another structurally related statin, the incidences of congenital anomalies, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> did not exceed those expected in the general population. However, the study was only able to exclude a 3 to 4 fold increased risk of congenital anomalies over the background rate. In 89% of these cases, drug treatment was initiated prior to pregnancy and was discontinued during the first trimester when pregnancy was identified.</p>
<dl>
<dt>Â </dt>
<dd>
<span class="Sup">2</span> Manson, J.M., Freyssinges, C., Ducrocq, M.B., Stephenson, W.P., Postmarketing     </dd>
<dt>Â </dt>
<dd>  Surveillance of Lovastatin and Simvastatin Exposure During Pregnancy, <span class="Italics">Reproductive </span>
</dd>
<dt>Â </dt>
<dd>
<span class="Italics">  Toxicology</span>, 10(6):439-446, 1996.</dd>
</dl>
<p>Simvastatin was not teratogenic in rats or rabbits at doses (25, 10 mg/kg/day, respectively) that resulted in 3 times the human exposure based on mg/m<span class="Sup">2</span> surface area. However, in studies with another structurally-related statin, skeletal malformations were observed in rats and mice. </p>
<p>Women of childbearing potential, who require treatment with simvastatin for a lipid disorder, should be advised to use effective contraception. For women trying to conceive, discontinuation of simvastatin should be considered. If pregnancy occurs, simvastatin should be immediately discontinued.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_29445cd0-a29a-4715-8f2c-ab15c3f5682d"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether simvastatin is excreted in human milk. Because a small amount of another drug in this class is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women taking simvastatin should not nurse their infants. A decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_f6194ef1-7ab9-4f4a-9fe2-36e3b9632851"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of simvastatin in patients 10 to 17 years of age with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> have been evaluated in a controlled clinical trial in adolescent boys and in girls who were at least 1 year post-<span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span>. Patients treated with simvastatin had an adverse reaction profile similar to that of patients treated with placebo. <span class="Bold">Doses greater than 40 mg have not been studied in this population</span>. In this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on menstrual cycle length in girls [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_3c571f87-3484-4860-8560-6e4b22866fea">2.5</a>), Adverse Reactions (<a href="#i4i_section_id_b535a642-856e-4db0-894e-2d6e8538fd9d">6.1</a>) and Clinical Studies (<a href="#i4i_section_id_f2cffe38-8f2c-4350-90eb-62ff9ec5a8ac">14.2</a>)</span>]. Adolescent females should be counseled on appropriate contraceptive methods while on simvastatin therapy [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>) and Use in Specific Populations (<a href="#i4i_pregnancy_id_582b44ca-1c11-4305-872a-60e20f694f1b">8.1</a>)</span>]. Simvastatin has not been studied in patients younger than 10 years of age, nor in pre-menarchal girls.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_bc83d7fb-cec3-4856-bad2-4388bdfb7bd8"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 2,423 patients who received simvastatin in Phase III clinical studies and the 10,269 patients in the Heart Protection Study who received simvastatin, 363 (15%) and 5,366 (52%), respectively were â‰¥ 65 years old. In HPS, 615 (6%) were â‰¥ 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Since advanced age (â‰¥ 65 years) is a predisposing factor for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, simvastatin should be prescribed with caution in the elderly [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>)</span>].</p>
<p>A pharmacokinetic study with simvastatin showed the mean plasma level of statin activity to be approximately 45% higher in elderly patients between 70 to 78 years of age compared with patients between 18 to 30 years of age. In 4S, 1,021 (23%) of 4,444 patients were 65 or older. Lipid-lowering efficacy was at least as great in elderly patients compared with younger patients, and simvastatin significantly reduced total mortality and CHD mortality in elderly patients with a history of CHD. In HPS, 52% of patients were elderly (4,891 patients 65 to 69 years and 5,806 patients 70 years or older). The relative risk reductions of CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, non-fatal MI, coronary and non-coronary revascularization procedures, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> were similar in older and younger patients [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_bf34010d-c2f4-42ac-9811-79b82a8a6ba7">14.1</a>)</span>]. In HPS, among 32,145 patients entering the active run-in period, there were 2 cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>; these patients were aged 67 and 73. Of the 7 cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> among 10,269 patients allocated to simvastatin, 4 were aged 65 or more (at baseline), of whom one was over 75. There were no overall differences in safety between older and younger patients in either 4S or HPS.</p>
<p>Because advanced age (â‰¥ 65 years) is a predisposing factor for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, simvastatin should be prescribed with caution in the elderly. In a clinical trial of patients treated with simvastatin 80 mg/day, patients â‰¥ 65 years of age had an increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, compared to patients &lt; 65 years of age [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4">12.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b215660-a7b5-4c2c-bc56-7349ef0f5732"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Caution should be exercised when simvastatin is administered to patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_ba553f70-4d45-4827-91e4-2a3806260f5b">2.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_570f1fa1-df08-4bb6-877e-c54a09b00e7a"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Simvastatin is contraindicated in patients with active liver disease which may include unexplained persistent elevations in hepatic transaminase levels [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>) and Warnings and Precautions (<a href="#i4i_section_id_23e33e00-d79a-4121-8637-fde4287bab81">5.2</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_1ba9460b-9e07-414e-bc6a-e4176db8cf72"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Significant lethality was observed in mice after a single oral dose of 9 g/m<span class="Sup">2</span>. No evidence of lethality was observed in rats or dogs treated with doses of 30 and 100 g/m<span class="Sup">2</span>, respectively. No specific diagnostic signs were observed in rodents. At these doses the only signs seen in dogs were <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and mucoid stools.</p>
<p>A few cases of overdosage with simvastatin have been reported; the maximum dose taken was 3.6 g. All patients recovered without sequelae. Supportive measures should be taken in the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. The dialyzability of simvastatin and its metabolites in man is not known at present.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_853b62ed-7868-4ed1-8e2e-c2147eca484b"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Simvastatin, USP is a lipid-lowering agent that is derived synthetically from a fermentation product of <span class="Italics">Aspergillus terreus. </span>After oral ingestion, simvastatin, USP, which is an inactive lactone, is hydrolyzed to the corresponding Î²-hydroxyacid form. This is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
<p>Simvastatin, USP is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2<span class="Italics">H</span>-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1<span class="Italics">S</span>-[1Î±,3Î±,7Î²,8Î²(2<span class="Italics">S</span><span class="Sup">*</span>,4<span class="Italics">S</span><span class="Sup">*</span>),-8aÎ²]]. Its structural formula is: </p>
<div class="Figure"><img alt="simvastatin structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6985b00-59b5-4ff3-a940-478c616fc227&amp;name=simvastatin-01.jpg"></div>
<p>C<span class="Sub">25</span>H<span class="Sub">38</span>O<span class="Sub">5</span>          M.W. 418.57</p>
<p>Simvastatin, USP is a white to off-white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol.</p>
<p>Simvastatin tablets USP for oral administration contain  5 mg of simvastatin, USP and the following inactive ingredients: ascorbic acid, butylated hydroxyanisole, citric acid monohydrate, hypromellose, iron oxide red, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, titanium dioxide and triacetin. Additionally the 5 mg, 10 mg, 20 mg, and 80 mg strengths contain: iron oxide yellow; and the 5 mg and 80 mg strengths contain: iron oxide black.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_fde3201a-0825-4bbc-bad5-19ac79c72edb"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_26613158-3ea0-4e31-b472-2a7a05203270"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Simvastatin is a prodrug and is hydrolyzed to its active Î²-hydroxyacid form, simvastatin acid, after administration. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. In addition, simvastatin reduces VLDL and TG and increases HDL-C.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_fec77cb8-80ca-4b1a-aa02-dac3eb7e79ea"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Epidemiological studies have demonstrated that elevated levels of total-C, LDL-C, as well as decreased levels of HDL-C are associated with the development of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> and increased cardiovascular risk. Lowering LDL-C decreases this risk. However, the independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_4e276302-1752-4c35-b4d7-0a43131208d4"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Simvastatin is a lactone that is readily hydrolyzed <span class="Italics">in vivo</span> to the corresponding Î²-hydroxyacid, a potent inhibitor of HMG-CoA reductase. Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the Î²-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.</p>
<p>Following an oral dose of <span class="Sup">14</span>C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces. Plasma concentrations of total radioactivity (simvastatin plus <span class="Sup">14</span>C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose. Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of the drug to the general circulation is low (&lt; 5%).</p>
<p>Both simvastatin and its Î²-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins. Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier.</p>
<p>The major active metabolites of simvastatin present in human plasma are the Î²-hydroxyacid of simvastatin and its 6Â´-hydroxy, 6Â´-hydroxymethyl, and 6Â´-exomethylene derivatives. Peak plasma concentrations of both active and total inhibitors were attained within 1.3 to 2.4 hours postdose. While the recommended therapeutic dose range is 5 to 40 mg/day, there was no substantial deviation from linearity of AUC of inhibitors in the general circulation with an increase in dose to as high as 120 mg. Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal.</p>
<p>In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18 to 30 years of age. Clinical study experience in the elderly (n = 1522), suggests that there were no overall differences in safety between elderly and younger patients [<span class="Italics">see Use in Specific Populations (<a href="#i4i_geriatric_use_id_bc83d7fb-cec3-4856-bad2-4388bdfb7bd8">8.5</a>)</span>].</p>
<p>Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (as measured by creatinine clearance).</p>
<p>Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is increased by high levels of HMG-CoA reductase inhibitory activity in plasma. Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>) and Drug Interactions (<a href="#i4i_section_id_15c84c1d-e705-4981-a677-dd3ee74cb043">7.1</a>)</span>].</p>
<a name="id_e5de8236-cf7e-4680-9b8b-ff161820865e"></a><table border="single" width="440">
<caption><span>TABLE 3: Effect of Coadministered Drugs or Grapefruit Juice on Simvastatin Systemic Exposure</span></caption>
<col width="20.5%">
<col width="22.0%">
<col width="16.1%">
<col width="18.4%">
<col width="8.2%">
<col width="14.8%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Results based on a chemical assay except results with propranolol as indicated.Â </dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>Results could be representative of the following CYP3A4 inhibitors: ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>Simvastatin acid refers to the Î²-hydroxyacid of simvastatin.Â </dd>
<dt><a name="footnote-4" href="#footnote-reference-4">Â§</a></dt>
<dd>The effect of amounts of grapefruit juice between those used in these two studies on simvastatin pharmacokinetics has not been studied.Â </dd>
<dt><a name="footnote-5" href="#footnote-reference-5">Â¶</a></dt>
<dd>Double-strength: one can of frozen concentrate diluted with one can of water. Grapefruit juice was administered TID for 2 days, and 200 mL together with single dose simvastatin and 30 and 90 minutes following single dose simvastatin on Day 3.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd>Single-strength: one can of frozen concentrate diluted with 3 cans of water. Grapefruit juice was administered with breakfast for 3 days, and simvastatin was administered in the evening on Day 3.Â </dd>
<dt><a name="footnote-7" href="#footnote-reference-7">Ãž</a></dt>
<dd>Because Chinese patients have an increased risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with simvastatin coadministered with lipid-modifying doses (â‰¥ 1 gram/day niacin) of niacin-containing products, and the risk is dose-related, Chinese patients should not receive simvastatin 80 mg coadministered with lipid-modifying doses of niacin-containing products [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>) and Drug Interactions (<a href="#i4i_section_id_df3960ee-c284-467b-b648-15d2bdf0db46">7.4</a>)</span>].</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Coadministered Drug or Grapefruit Juice </span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle"><span class="Bold">Dosing of Coadministered Drug or Grapefruit Juice </span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle"><span class="Bold">Dosing of Simvastatin </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">Geometric Mean Ratio (Ratio<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> with/without coadministered drug) No Effect = 1</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Â  </td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">AUC </span></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">C<span class="Sub">max</span></span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="6" valign="top">
<span class="Bold">Contraindicated with simvastatin </span>[<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>) and Warnings and Precautions (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>)</span>] </td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Telithromycin<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">200 mg QD for 4 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">80 mg</td>
<td class="Rrule" align="left" valign="top">simvastatin acid<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a>
</td>
<td class="Rrule" align="center" valign="top">12</td>
<td class="Rrule" align="center" valign="top">15</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">8.9</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">5.3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Nelfinavir<a href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">1250 mg BID for 14 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">20 mg QD for 28 days</td>
<td class="Rrule" align="left" valign="top">simvastatin acid<a href="#footnote-3" class="Sup">â€¡</a>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">6.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Itraconazole<a href="#footnote-2" class="Sup">â€ </a>Â  </td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">200 mg QD for 4 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">80 mg</td>
<td class="Rrule" align="left" valign="top">simvastatin acid<a href="#footnote-3" class="Sup">â€¡</a>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">13.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">13.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="4" valign="top">Posaconazole</td>
<td class="Rrule" align="center" rowspan="2" valign="top">100 mg (oral suspension) QD for 13 days</td>
<td class="Rrule" align="center" rowspan="2" valign="top">40 mg</td>
<td class="Rrule" align="left" valign="top">simvastatin acid</td>
<td class="Rrule" align="center" valign="top">7.3</td>
<td class="Rrule" align="center" valign="top">9.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">10.3</td>
<td class="Botrule Rrule" align="center" valign="top">9.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" rowspan="2" valign="top">200 mg (oral suspension) QD for 13 days</td>
<td class="Rrule" align="center" rowspan="2" valign="top">40 mg</td>
<td class="Rrule" align="left" valign="top">simvastatin acid</td>
<td class="Rrule" align="center" valign="top">8.5</td>
<td class="Rrule" align="center" valign="top">9.5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">10.6</td>
<td class="Botrule Rrule" align="center" valign="top">11.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Gemfibrozil</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">600 mg BID for 3 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">40 mg</td>
<td class="Rrule" align="left" valign="top">simvastatin acid</td>
<td class="Rrule" align="center" valign="top">2.85</td>
<td class="Rrule" align="center" valign="top">2.18</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">1.35</td>
<td class="Botrule Rrule" align="center" valign="top">0.91</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid grapefruit juice with simvastatin</span> [<span class="Italics">see Warnings and Precautions (<span class="Italics"><a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a></span></span><span class="Italics">)</span>]</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Grapefruit Juice<a name="footnote-reference-4" href="#footnote-4" class="Sup">Â§</a>Â  (high dose) </td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">200 mL of double-strength TID<a name="footnote-reference-5" href="#footnote-5" class="Sup">Â¶</a>
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">60 mg single dose</td>
<td class="Rrule" align="left" valign="top">simvastatin acid </td>
<td class="Rrule" align="center" valign="top">7</td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Grapefruit Juice<a href="#footnote-4" class="Sup">Â§</a> (low dose) </td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">8 oz (about 237 mL) of single-strength<a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a>
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">20 mg single dose</td>
<td class="Rrule" align="left" valign="top">simvastatin acid </td>
<td class="Rrule" align="center" valign="top">1.3</td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">1.9</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid taking with &gt; 10 mg simvastatin</span>, based on clinical and/or postmarketing experience [<span class="Italics">see Warnings and Precautions <span class="Italics">(<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>)</span></span>]</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Verapamil SR </td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"> 240 mg QD Days 1 to 7 then 240 mg BID on Days 8 to 10 </td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"> 80 mg on Day 10 </td>
<td class="Rrule" align="left" valign="top">simvastatin acid </td>
<td class="Rrule" align="center" valign="top">2.3</td>
<td class="Rrule" align="center" valign="top">2.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">2.5</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">2.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Diltiazem</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">120 mg BID for 10 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">80 mg on Day 10</td>
<td class="Rrule" align="left" valign="top">simvastatin acid </td>
<td class="Rrule" align="center" valign="top">2.69</td>
<td class="Rrule" align="center" valign="top">2.69</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">3.1</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">2.88</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Diltiazem</td>
<td class="Botrule Rrule" align="center" valign="top">120 mg BID for 14 days</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg on Day 14</td>
<td class="Botrule Rrule" align="left" valign="top">simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">4.6</td>
<td class="Botrule Rrule" align="center" valign="top">3.6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Dronedarone</td>
<td class="Botrule Rrule" align="left" valign="top">400 mg BID for 14 days</td>
<td class="Botrule Rrule" align="left" valign="top">40 mg QD for 14 days</td>
<td class="Botrule Rrule" align="left" valign="top"><p class="First">Simvastatin acid simvastatin</p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">1.96</p>3.9</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">2.14</p>3.75</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid taking with &gt; 20 mg simvastatin</span>, based on clinical and/or postmarketing experience [<span class="Italics">see Warnings and Precautions <span class="Italics">(<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>)</span></span>]simvastatin 3.102.88</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Amiodarone</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">400 mg QD for 3 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">40 mg on Day 3</td>
<td class="Rrule" align="left" valign="top">simvastatin acid</td>
<td class="Rrule" align="center" valign="top">1.75</td>
<td class="Rrule" align="center" valign="top">1.72</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">1.76</td>
<td class="Botrule Rrule" align="center" valign="top">1.79</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Amlodipine</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">10 mg QD x 10 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">80 mg on Day 10</td>
<td class="Rrule" align="left" valign="top">simvastatin acid</td>
<td class="Rrule" align="center" valign="top">1.58</td>
<td class="Rrule" align="center" valign="top">1.56</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">1.77</td>
<td class="Botrule Rrule" align="center" valign="top">1.47</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Ranolazine SR</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">1000 mg BID for 7 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">80 mg on Day 1 and Day 6 to 9</td>
<td class="Rrule" align="left" valign="top">simvastatin acid</td>
<td class="Rrule" align="center" valign="top">2.26</td>
<td class="Rrule" align="center" valign="top">2.28</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">1.86</td>
<td class="Botrule Rrule" align="center" valign="top">1.75</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="6" valign="top"><span class="Bold">No dosing adjustments required for the following: </span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Fenofibrate </td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">160 mg QD X 14 days</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">80 mg QD on Days 8 to 14</td>
<td class="Rrule" align="left" valign="top">simvastatin acid </td>
<td class="Rrule" align="center" valign="top">0.64</td>
<td class="Rrule" align="center" valign="top">0.89</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">0.89</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">0.83</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Niacin extended-release<a name="footnote-reference-7" href="#footnote-7" class="Sup">Ãž</a>
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">2 g single dose</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">20 mg single dose</td>
<td class="Rrule" align="left" valign="top">simvastatin acid </td>
<td class="Rrule" align="center" valign="top">1.6</td>
<td class="Rrule" align="center" valign="top">1.84</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">1.4</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">1.08</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Propranolol </td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">80 mg single dose</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">80 mg single dose</td>
<td class="Rrule" align="left" valign="top">total inhibitor </td>
<td class="Rrule" align="center" valign="top">0.79</td>
<td class="Rrule" align="center" valign="top">â†“ from 33.6 to 21.1 ngâ€¢eq/mL</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">active inhibitor </td>
<td class="Botrule Rrule" align="center" valign="top">0.79</td>
<td class="Botrule Rrule" align="center" valign="top">â†“ from 7 to 4.7 ngâ€¢eq/mL</td>
</tr>
</tbody>
</table>
<p>In a study of 12 healthy volunteers, simvastatin at the 80 mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin. This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4. </p>
<p>Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_e458f006-d0e7-4ab3-8104-33b41bc0067a"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_0abcfc93-8c43-47b2-8e93-526033ec0552"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 72 week carcinogenicity study, mice were administered daily doses of simvastatin of 25, 100, and 400 mg/kg body weight, which resulted in mean plasma drug levels approximately 1, 4, and 8 times higher than the mean human plasma drug level, respectively (as total inhibitory activity based on AUC) after an 80 mg oral dose. <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">Liver carcinomas</span> were significantly increased in high-dose females and mid- and high-dose males with a maximum incidence of 90% in males. The incidence of <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of the liver was significantly increased in mid- and high-dose females. Drug treatment also significantly increased the incidence of lung <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in mid- and high-dose males and females. <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">Adenomas</span> of the Harderian gland (a gland of the eye of rodents) were significantly higher in high-dose mice than in controls. No evidence of a tumorigenic effect was observed at 25 mg/kg/day.Â </p>
<p>Â In a separate 92 week carcinogenicity study in mice at doses up to 25 mg/kg/day, no evidence of a tumorigenic effect was observed (mean plasma drug levels were 1 times higher than humans given 80 mg simvastatin as measured by AUC).Â </p>
<p>Â In a two-year study in rats at 25 mg/kg/day, there was a statistically significant increase in the incidence of thyroid follicular <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in female rats exposed to approximately 11 times higher levels of simvastatin than in humans given 80 mg simvastatin (as measured by AUC).</p>
<p>A second two-year rat carcinogenicity study with doses of 50 and 100 mg/kg/day produced <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and carcinomas (in female rats at both doses and in males at 100 mg/kg/day). Thyroid follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were increased in males and females at both doses; thyroid follicular cell carcinomas were increased in females at 100 mg/kg/day. The increased incidence of thyroid neoplasms appears to be consistent with findings from other statins. These treatment levels represented plasma drug levels (AUC) of approximately 7 and 15 times (males) and 22 and 25 times (females) the mean human plasma drug exposure after an 80 milligram daily dose.Â </p>
<p>No evidence of mutagenicity was observed in a microbial mutagenicity (Ames) test with or without rat or mouse liver metabolic activation. In addition, no evidence of damage to genetic material was noted in an Â <span class="Italics">in vitroÂ </span>Â  alkaline elution assay using rat hepatocytes, a V-79 mammalian cell forward mutation study, an <span class="Italics">in vitroÂ </span>Â  chromosome aberration study in CHO cells, or an Â <span class="Italics">in vivoÂ </span>Â  chromosomal aberration assay in mouse bone marrow.Â </p>
<p>Â There was decreased fertility in male rats treated with simvastatin for 34 weeks at 25 mg/kg body weight (4 times the maximum human exposure level, based on AUC, in patients receiving 80 mg/day); however, this effect was not observed during a subsequent fertility study in which simvastatin was administered at this same dose level to male rats for 11 weeks (the entire cycle of spermatogenesis including epididymal maturation). No microscopic changes were observed in the testes of rats from either study. At 180 mg/kg/day, (which produces exposure levels 22 times higher than those in humans taking 80 mg/day based on surface area, mg/mÂ <span class="Sup">2Â </span>Â ), seminiferous tubule degeneration (<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and loss of spermatogenic epithelium) was observed. In dogs, there was drug-related <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>, decreased spermatogenesis, spermatocytic degeneration and giant cell formation at 10 mg/kg/day, (approximately 2 times the human exposure, based on AUC, at 80 mg/day). The clinical significance of these findings is unclear.Â </p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_8b115870-75c5-40cc-8249-9d5697b01a3f"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Italics">CNS Toxicity </span></p>
<p>Optic nerve degeneration was seen in clinically normal dogs treated with simvastatin for 14 weeks at 180 mg/kg/day, a dose that produced mean plasma drug levels about 12 times higher than the mean plasma drug level in humans taking 80 mg/day. </p>
<p>A chemically similar drug in this class also produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion starting at 60 mg/kg/day, a dose that produced mean plasma drug levels about 30 times higher than the mean plasma drug level in humans taking the highest recommended dose (as measured by total enzyme inhibitory activity). This same drug also produced vestibulocochlear Wallerian-like degeneration and retinal <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> cell chromatolysis in dogs treated for 14 weeks at 180 mg/kg/day, a dose that resulted in a mean plasma drug level similar to that seen with the 60 mg/kg/day dose. </p>
<p>CNS vascular lesions, characterized by perivascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, mononuclear cell infiltration of perivascular spaces, perivascular fibrin deposits and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of small vessels were seen in dogs treated with simvastatin at a dose of 360 mg/kg/day, a dose that produced mean plasma drug levels that were about 14 times higher than the mean plasma drug levels in humans taking 80 mg/day. Similar CNS vascular lesions have been observed with several other drugs of this class. </p>
<p>There were <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> in female rats after two years of treatment with 50 and 100 mg/kg/day (22 and 25 times the human AUC at 80 mg/day, respectively) and in dogs after three months at 90 mg/kg/day (19 times) and at two years at 50 mg/kg/day (5 times).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_0d2adc7b-f70c-4359-96c8-2ccaa774eb6b"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf34010d-c2f4-42ac-9811-79b82a8a6ba7"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Clinical Studies in Adults</h2>
<p class="First"><span class="Italics">Reductions in Risk of CHD Mortality and Cardiovascular Events</span></p>
<p>In 4S, the effect of therapy with simvastatin on total mortality was assessed in 4,444 patients with CHD and baseline total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> 212 to 309 mg/dL (5.5 to 8 mmol/L). In this multicenter, randomized, double-blind, placebo-controlled study, patients were treated with standard care, including diet, and either simvastatin 20 to 40 mg/day (n = 2,221) or placebo (n = 2,223) for a median duration of 5.4 years. Over the course of the study, treatment with simvastatin led to mean reductions in total-C, LDL-C and TG of 25%, 35%, and 10%, respectively, and a mean increase in HDL-C of 8%. Simvastatin significantly reduced the risk of mortality by 30% (p = 0.0003, 182 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the simvastatin group vs 256 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the placebo group). The risk of CHD mortality was significantly reduced by 42% (p = 0.00001, 111 vs 189 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>). There was no statistically significant difference between groups in non-cardiovascular mortality. Simvastatin significantly decreased the risk of having major coronary events (CHD mortality plus hospital-verified and silent non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> [MI]) by 34% (p &lt; 0.00001, 431 vs 622 patients with one or more events). The risk of having a hospital-verified non-fatal MI was reduced by 37%. Simvastatin significantly reduced the risk for undergoing myocardial revascularization procedures (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty) by 37% (p &lt; 0.00001, 252 vs 383 patients). Simvastatin significantly reduced the risk of fatal plus non-fatal cerebrovascular events (combined <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span>) by 28% (p = 0.033, 75 vs 102 patients). Simvastatin reduced the risk of major coronary events to a similar extent across the range of baseline total and LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels. Because there were only 53 female <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, the effect of simvastatin on mortality in women could not be adequately assessed. However, simvastatin significantly lessened the risk of having major coronary events by 34% (60 vs 91 women with one or more event). The randomization was stratified by angina alone (21% of each treatment group) or a previous MI. Because there were only 57 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> among the patients with angina alone at baseline, the effect of simvastatin on mortality in this subgroup could not be adequately assessed. However, trends in reduced coronary mortality, major coronary events and revascularization procedures were consistent between this group and the total study cohort. Additionally, simvastatin resulted in similar decreases in relative risk for total mortality, CHD mortality, and major coronary events in elderly patients (â‰¥ 65 years), compared with younger patients.</p>
<p>The Heart Protection Study (HPS) was a large, multi-center, placebo-controlled, double-blind study with a mean duration of 5 years conducted in 20,536 patients (10,269 on simvastatin 40 mg and 10,267 on placebo). Patients were allocated to treatment using a covariate adaptive method<span class="Sup">3</span> which took into account the distribution of 10 important baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients had a mean age of 64 years (range 40 to 80 years), were 97% Caucasian and were at high risk of developing a major coronary event because of existing CHD (65%), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (Type 2, 26%; Type 1, 3%), history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or other cerebrovascular disease (16%), peripheral vessel disease (33%), or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in males â‰¥ 65 years (6%). At baseline, 3,421 patients (17%) had LDL-C levels below 100 mg/dL, of whom 953 (5%) had LDL-C levels below 80 mg/dL; 7,068 patients (34%) had levels between 100 and 130 mg/dL; and 10,047 patients (49%) had levels greater than 130 mg/dL.</p>
<dl>
<dt>Â </dt>
<dd>
<span class="Sup">3</span> D.R. Taves, Minimization: a new method of assigning patients to treatment and control </dd>
<dt>Â </dt>
<dd>  groups. Clin. Pharmacol. Ther. 15 (1974), pp. 443-453</dd>
</dl>
<p>The HPS results showed that simvastatin 40 mg/day significantly reduced: total and CHD mortality; nonÂ­fatal MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and revascularization procedures (coronary and non-coronary) (see <span class="Bold"><a href="#id_abc67204-6022-4aee-9e0a-bdd1fefcc014">TABLE 4</a></span>). </p>
<a name="id_abc67204-6022-4aee-9e0a-bdd1fefcc014"></a><table border="1" width="441">
<caption><span>TABLE 4: Summary of Heart Protection Study Results</span></caption>
<col width="32.9%">
<col width="17.2%">
<col width="15.9%">
<col width="17.7%">
<col width="16.3%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>n = number of patients with indicated event</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Endpoint </span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Simvastatin</span></p>
<p>(N = 10,269)</p>
<p>n (%)<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p>Â (N = 10,267)</p>
<p>n (%)<a href="#footnote-8" class="Sup">*</a></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Risk Reduction</span></p>
<p><span class="Bold">(%) (95% CI)</span>Â </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">p-Value </span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold">Primary </span></td>
<td class="Rrule" align="center" valign="middle"> Â  </td>
<td class="Rrule" align="center" valign="middle"> Â  </td>
<td class="Rrule" align="center" valign="middle"> Â  </td>
<td class="Rrule" align="center" valign="middle"> Â  </td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   Mortality </td>
<td class="Rrule" align="center" valign="middle"> 1,328 (12.9) </td>
<td class="Rrule" align="center" valign="middle"> 1,507 (14.7) </td>
<td class="Rrule" align="center" valign="middle"> 13 (6 to 19) </td>
<td class="Rrule" align="center" valign="middle"> p = 0.0003 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   CHD mortality </td>
<td class="Botrule Rrule" align="center" valign="middle"> 587 (5.7) </td>
<td class="Botrule Rrule" align="center" valign="middle"> 707 (6.9) </td>
<td class="Botrule Rrule" align="center" valign="middle"> 18 (8 to 26) </td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"> p = 0.0005 </td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold">Secondary </span></td>
<td class="Rrule" align="center" valign="middle"> Â  </td>
<td class="Rrule" align="center" valign="middle"> Â  </td>
<td class="Rrule" align="center" valign="middle"> Â  </td>
<td class="Rrule" align="center" valign="middle"> Â  </td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   Non-fatal MI </td>
<td class="Rrule" align="center" valign="middle"> 357 (3.5) </td>
<td class="Rrule" align="center" valign="middle"> 574 (5.6) </td>
<td class="Rrule" align="center" valign="middle"> 38 (30 to 46) </td>
<td class="Rrule" align="center" valign="middle"> p &lt; 0.0001 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 444 (4.3) </td>
<td class="Botrule Rrule" align="center" valign="middle"> 585 (5.7) </td>
<td class="Botrule Rrule" align="center" valign="middle"> 25 (15 to 34) </td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"> p &lt; 0.0001 </td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold">Tertiary</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   Coronary revascularization </td>
<td class="Rrule" align="center" valign="middle"> 513 (5) </td>
<td class="Rrule" align="center" valign="middle"> 725 (7.1) </td>
<td class="Rrule" align="center" valign="middle"> 30 (22 to 38) </td>
<td class="Rrule" align="center" valign="middle"> p &lt; 0.0001 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">   Peripheral and other non-coronary revascularization </td>
<td class="Botrule Rrule" align="center" valign="middle"> 450 (4.4) </td>
<td class="Botrule Rrule" align="center" valign="middle"> 532 (5.2) </td>
<td class="Botrule Rrule" align="center" valign="middle"> 16 (5 to 26) </td>
<td class="Botrule Rrule" align="center" valign="middle"> p = 0.006 </td>
</tr>
</tbody>
</table>
<p>Two composite endpoints were defined in order to have sufficient events to assess relative risk reductions across a range of baseline characteristics (see <span class="Bold"><a href="#id_f4037b35-c62d-4ad2-9b94-0bfb2e92e54e">Figure 1</a></span>). A composite of major coronary events (MCE) was comprised of CHD mortality and non-fatal MI (analyzed by time-to-first event; 898 patients treated with simvastatin had events and 1,212 patients on placebo had events). A composite of major vascular events (MVE) was comprised of MCE, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and revascularization procedures including coronary, peripheral and other non-coronary procedures (analyzed by time-to-first event; 2,033 patients treated with simvastatin had events and 2,585 patients on placebo had events). Significant relative risk reductions were observed for both composite endpoints (27% for MCE and 24% for MVE, p &lt; 0.0001). Treatment with simvastatin produced significant relative risk reductions for all components of the composite endpoints. The risk reductions produced by simvastatin in both MCE and MVE were evident and consistent regardless of cardiovascular disease related medical history at study entry (i.e., CHD alone; or <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, cerebrovascular disease, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or treated <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, with or without CHD), gender, age, creatinine levels up to the entry limit of 2.3 mg/dL, baseline levels of LDL-C, HDL-C, <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B and A-1, baseline concomitant cardiovascular medications (i.e., aspirin, beta blockers, or calcium channel blockers), smoking status, alcohol intake, or <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>. Diabetics showed risk reductions for MCE and MVE due to simvastatin treatment regardless of baseline HbA1c levels or <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> with the greatest effects seen for diabetics without CHD.</p>
<div class="Figure">
<img alt="Figure 1: The Effects of Treatment With Simvastatin on Major Vascular Events and Major Coronary Events in HPS" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6985b00-59b5-4ff3-a940-478c616fc227&amp;name=simvastatin-02.jpg"><p class="MultiMediaCaption">Figure 1: The Effects of Treatment With Simvastatin on Major Vascular Events and Major Coronary Events in HPS</p>
</div>
<p>N = number of patients in each subgroup. The inverted triangles are point estimates of the relative risk, with their 95% confidence intervals represented as a line. The area of a triangle is proportional to the number of patients with MVE or MCE in the subgroup relative to the number with MVE or MCE, respectively, in the entire study population. The vertical solid line represents a relative risk of one. The vertical dashed line represents the point estimate of relative risk in the entire study population.</p>
<p><span class="Italics">Angiographic Studies </span></p>
<p>In the Multicenter Anti-Atheroma Study, the effect of simvastatin on <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> was assessed by quantitative coronary angiography in hypercholesterolemic patients with CHD. In this randomized, double-blind, controlled study, patients were treated with simvastatin 20 mg/day or placebo. Angiograms were evaluated at baseline, two and four years. The co-primary study endpoints were mean change per-patient in minimum and mean lumen diameters, indicating focal and diffuse disease, respectively. Simvastatin significantly slowed the progression of lesions as measured in the Year 4 angiogram by both parameters, as well as by change in percent diameter stenosis. In addition, simvastatin significantly decreased the proportion of patients with new lesions and with new total occlusions. </p>
<p><span class="Italics">Modifications of Lipid Profiles </span></p>
<p><span class="Italics">Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Fredrickson type IIa and IIb)</span></p>
<p>Simvastatin has been shown to be effective in reducing total-C and LDL-C in heterozygous familial and non-familial forms of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and in mixed <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. Maximal to near maximal response is generally achieved within 4 to 6 weeks and maintained during chronic therapy. Simvastatin consistently and significantly decreased total-C, LDL-C, total-C/HDL-C ratio, and LDL-C/HDL-C ratio; simvastatin also decreased TG and increased HDL-C (see <span class="Bold"><a href="#id_7b470014-4994-40db-a22e-2011386c9942">TABLE 5</a></span>).</p>
<a name="id_7b470014-4994-40db-a22e-2011386c9942"></a><table border="1" width="437">
<caption><span>TABLE 5: Mean Response in Patients With Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> and Combined (Mixed) <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean Percent Change From Baseline After 6 to 24 Weeks)</span></caption>
<col width="38.2%">
<col width="12.6%">
<col width="14.4%">
<col width="12.1%">
<col width="12.6%">
<col width="10.1%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>median percent change</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">â€ </a></dt>
<dd>mean baseline LDL-C 244 mg/dL and median baseline TG 168 mg/dL</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">â€¡</a></dt>
<dd>mean baseline LDL-C 188 mg/dL and median baseline TG 128 mg/dL</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">Â§</a></dt>
<dd>mean baseline LDL-C 226 mg/dL and median baseline TG 156 mg/dL</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">Â¶</a></dt>
<dd>21% and 36% median reduction in TG in patients with TG â‰¤ 200 mg/dL and TG &gt; 200 mg/dL, respectively. Patients with TG &gt; 350 mg/dL were excluded</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">#</a></dt>
<dd>mean baseline LDL-C 156 mg/dL and median baseline TG 391 mg/dL.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="middle">TREATMENT</td>
<td class="Botrule" align="center" valign="middle">N</td>
<td class="Botrule" align="center" valign="middle">TOTAL-C</td>
<td class="Botrule" align="center" valign="middle">LDL-C</td>
<td class="Botrule" align="center" valign="middle">HDL-C</td>
<td class="Botrule Rrule" align="center" valign="middle">TG<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Underline">Lower</span><span class="Underline">Dose</span><span class="Underline">Comparative</span><span class="Underline">Study</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">â€ </a>
</td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle"><span class="Underline">(Mean % Change at Week 6)</span></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Bold">Simvastatin</span> 5 mg q.p.m.</td>
<td align="center" valign="middle">109</td>
<td align="center" valign="middle">-19</td>
<td align="center" valign="middle">-26</td>
<td align="center" valign="middle">10</td>
<td class="Rrule" align="center" valign="middle">-12</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Bold">Simvastatin</span> 10 mg q.p.m.</td>
<td align="center" valign="middle">110</td>
<td align="center" valign="middle">-23</td>
<td align="center" valign="middle">-30</td>
<td align="center" valign="middle">12</td>
<td class="Rrule" align="center" valign="middle">-15</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Underline">Scandinavian Simvastatin Survival Study</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">â€¡</a>
</td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle"><span class="Underline">(Mean % Change at Week 6)</span></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">Placebo</td>
<td align="center" valign="middle">2223</td>
<td align="center" valign="middle">-1</td>
<td align="center" valign="middle">-1</td>
<td align="center" valign="middle">0</td>
<td class="Rrule" align="center" valign="middle">-2</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Bold">Simvastatin</span> 20 mg q.p.m.</td>
<td align="center" valign="middle">2221</td>
<td align="center" valign="middle">-28</td>
<td align="center" valign="middle">-38</td>
<td align="center" valign="middle">8</td>
<td class="Rrule" align="center" valign="middle">-19</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Underline">Upper Dose Comparative Study</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">Â§</a>
</td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle"><span class="Underline">(Mean % Change Averaged at Weeks 18 and 24)</span></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Bold">Simvastatin</span> 40 mg q.p.m.</td>
<td align="center" valign="middle">433</td>
<td align="center" valign="middle">-31</td>
<td align="center" valign="middle">-41</td>
<td align="center" valign="middle">9</td>
<td class="Rrule" align="center" valign="middle">-18</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Bold">Simvastatin</span> 80 mg q.p.m.<a name="footnote-reference-13" href="#footnote-13" class="Sup">Â¶</a>
</td>
<td align="center" valign="middle">664</td>
<td align="center" valign="middle">-36</td>
<td align="center" valign="middle">-47</td>
<td align="center" valign="middle">8</td>
<td class="Rrule" align="center" valign="middle">-24</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Underline">Multi-Center</span><span class="Underline">Combined</span><span class="Underline">Hyperlipidemi</span><span class="Underline">a Study</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">#</a>
</td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle"><span class="Underline">(Mean % Change at Week 6)</span></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">Placebo</td>
<td align="center" valign="middle">125</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">3</td>
<td class="Rrule" align="center" valign="middle">-4</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Bold">Simvastatin</span> 40 mg q.p.m.</td>
<td align="center" valign="middle">123</td>
<td align="center" valign="middle">-25</td>
<td align="center" valign="middle">-29</td>
<td align="center" valign="middle">13</td>
<td class="Rrule" align="center" valign="middle">-28</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="middle">
<span class="Bold">Simvastatin</span> 80 mg q.p.m.</td>
<td align="center" valign="middle">124</td>
<td align="center" valign="middle">-31</td>
<td align="center" valign="middle">-36</td>
<td align="center" valign="middle">16</td>
<td class="Botrule Rrule" align="center" valign="middle">-33</td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (Fredrickson type IV) </span></p>
<p>The results of a subgroup analysis in 74 patients with type IV <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> from a 130 patient, double-blind, placebo-controlled, 3 period crossover study are presented in <span class="Bold">TABLE 6</span>.</p>
<a name="id_478e41be-a4fc-4283-83d7-d23787478b42"></a><table border="1" width="438">
<caption><span>TABLE 6: Six-Week, Lipid-Lowering Effects of Simvastatin in Type IV <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> Median Percent Change (25<span class="Sup">th</span> and 75<span class="Sup">th</span> Percentile) From Baseline<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a></span></caption>
<col width="15.5%">
<col width="5.7%">
<col width="11.6%">
<col width="13.5%">
<col width="13.2%">
<col width="11.4%">
<col width="13.2%">
<col width="15.8%">
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>The median baseline values (mg/dL) for the patients in this study were: total-C = 254, LDL-C = 135, HDL-C = 36, TG = 404, VLDL-C = 83, and non-HDL-C = 215.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="middle">TREATMENT</td>
<td class="Botrule" align="center" valign="middle">N</td>
<td class="Botrule" align="center" valign="middle">Total-C</td>
<td class="Botrule" align="center" valign="middle">LDL-C</td>
<td class="Botrule" align="center" valign="middle">HDL-C</td>
<td class="Botrule" align="center" valign="middle">TG</td>
<td class="Botrule" align="center" valign="middle">VLDL-C</td>
<td class="Botrule Rrule" align="center" valign="middle">Non-HDL-C</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">Placebo</td>
<td align="center" valign="middle">74</td>
<td align="center" valign="middle">
<p class="First">+2</p>
<p>(-7, +7)</p>
</td>
<td align="center" valign="middle">
<p class="First">+1</p>
<p>(-8, +14)</p>
</td>
<td align="center" valign="middle">
<p class="First">+3</p>
<p>(-3, +10)</p>
</td>
<td align="center" valign="middle">
<p class="First">-9</p>
<p>(-25, +13)</p>
</td>
<td align="center" valign="middle">
<p class="First">-7</p>
<p>(-25, +11)</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">+1</p>
<p>(-9, +8)</p>
</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">Simvastatin 40 mg/day</td>
<td align="center" valign="middle">74</td>
<td align="center" valign="middle">
<p class="First">-25</p>
<p>(-34, -19)</p>
</td>
<td align="center" valign="middle">
<p class="First">-28</p>
<p>(-40, -17)</p>
</td>
<td align="center" valign="middle">
<p class="First">+11</p>
<p>(+5, +23)</p>
</td>
<td align="center" valign="middle">
<p class="First">-29</p>
<p>(-43, -16)</p>
</td>
<td align="center" valign="middle">
<p class="First">-37</p>
<p>(-54, -23)</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">-32</p>
<p>(-42, -23)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="middle">Simvastatin 80 mg/day</td>
<td align="center" valign="middle">74</td>
<td align="center" valign="middle">
<p class="First">-32</p>
<p>(-38, -24)</p>
</td>
<td align="center" valign="middle">
<p class="First">-37</p>
<p>(-46, -26)</p>
</td>
<td align="center" valign="middle">
<p class="First">+15</p>
<p>(+5, +23)</p>
</td>
<td align="center" valign="middle">
<p class="First">-34</p>
<p>(-45, -18)</p>
</td>
<td align="center" valign="middle">
<p class="First">-41</p>
<p>(-57, -28)</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">-38</p>
<p>(-49, -32)</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Dysbetalipoproteinemia (Fredrickson type III) </span></p>
<p>The results of a subgroup analysis in 7 patients with type III <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (dysbetalipoproteinemia) (apo E2/2) (VLDL-C/TG &gt; 0.25) from a 130 patient, double-blind, placebo-controlled, 3 period crossover study are presented in <span class="Bold">TABLE 7</span>.</p>
<a name="id_0077bc34-4c36-46d0-aa03-49173e246daf"></a><table border="1" width="441">
<caption><span>TABLE 7: Six-Week, Lipid-Lowering Effects of Simvastatin in Type III <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> Median Percent Change (Min, Max) From Baseline<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a></span></caption>
<col width="19.3%">
<col width="5.7%">
<col width="9.5%">
<col width="13.4%">
<col width="11.6%">
<col width="9.1%">
<col width="13.8%">
<col width="17.7%">
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>The median baseline values (mg/dL) were: total-C = 324, LDL-C = 121, HDL-C = 31, TG = 411, VLDL-C = 170, and non-HDL-C = 291.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="top">TREATMENT </td>
<td class="Botrule" align="center" valign="top">N </td>
<td class="Botrule" align="center" valign="top"> Total-C </td>
<td class="Botrule" align="center" valign="top"> LDL-C + IDL </td>
<td class="Botrule" align="center" valign="top"> HDL-C </td>
<td class="Botrule" align="center" valign="top"> TG </td>
<td class="Botrule" align="center" valign="top"> VLDL-C + IDL </td>
<td class="Botrule Rrule" align="center" valign="top"> Non-HDL-C </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">Placebo </td>
<td align="center" valign="middle">7 </td>
<td align="center" valign="middle">
<p class="First">-8</p>
<p>(-24, +34)</p>
</td>
<td align="center" valign="middle">
<p class="First">-8</p>
<p>(-27, +23) </p>
</td>
<td align="center" valign="middle">
<p class="First">-2</p>
<p>(-21, +16) </p>
</td>
<td align="center" valign="middle">
<p class="First">+4</p>
<p>(-22, +90) </p>
</td>
<td align="center" valign="middle">
<p class="First">-4</p>
<p>(-28, +78) </p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">-8</p>
<p>(-26, -39) </p>
</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">Simvastatin 40 mg/day </td>
<td align="center" valign="middle">7 </td>
<td align="center" valign="middle">
<p class="First">-50</p>
<p>(-66, -39)</p>
</td>
<td align="center" valign="middle">
<p class="First">-50</p>
<p>(-60, -31) </p>
</td>
<td align="center" valign="middle">
<p class="First">+7</p>
<p>(-8, +23)</p>
</td>
<td align="center" valign="middle">
<p class="First">-41</p>
<p>(-74, -16)</p>
</td>
<td align="center" valign="middle">
<p class="First">-58</p>
<p>(-90, -37)</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">-57</p>
<p>(-72, -44)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="middle">Simvastatin 80 mg/day </td>
<td align="center" valign="middle">7 </td>
<td align="center" valign="middle">
<p class="First">-52</p>
<p>(-55, -41) </p>
</td>
<td align="center" valign="middle">
<p class="First">-51</p>
<p>(-57, -28) </p>
</td>
<td align="center" valign="middle">
<p class="First"> +7</p>
<p>(-5, +29) </p>
</td>
<td align="center" valign="middle">
<p class="First"> -38</p>
<p>(-58, +2) </p>
</td>
<td align="center" valign="middle">
<p class="First"> -60</p>
<p>(-72, -39) </p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First"> -59</p>
<p>(-61, -46) </p>
</td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></span></p>
<p>In a controlled clinical study, 12 patients 15 to 39 years of age with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> received simvastatin 40 mg/day in a single dose or in 3 divided doses, or 80 mg/day in 3 divided doses. In 11 patients with reductions in LDL-C, the mean LDL-C changes for the 40 and 80 mg doses were 14% (range 8% to 23%, median 12%) and 30% (range 14% to 46%, median 29%), respectively. One patient had an increase of 15% in LDL-C. Another patient with absent LDL-C receptor function had an LDL-C reduction of 41% with the 80 mg dose.</p>
<p><span class="Italics">Endocrine Function</span></p>
<p>In clinical studies, simvastatin did not impair adrenal reserve or significantly reduce basal plasma cortisol concentration. Small reductions from baseline in basal plasma testosterone in men were observed in clinical studies with simvastatin, an effect also observed with other statins and the bile acid sequestrant cholestyramine. There was no effect on plasma gonadotropin levels. In a placebo-controlled, 12 week study there was no significant effect of simvastatin 80 mg on the plasma testosterone response to human chorionic gonadotropin. In another 24 week study, simvastatin 20 to 40 mg had no detectable effect on spermatogenesis. In 4S, in which 4,444 patients were randomized to simvastatin 20 to 40 mg/day or placebo for a median duration of 5.4 years, the incidence of male sexual adverse events in the two treatment groups was not significantly different. Because of these factors, the small changes in plasma testosterone are unlikely to be clinically significant. The effects, if any, on the pituitary-gonadal axis in pre-menopausal women are unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2cffe38-8f2c-4350-90eb-62ff9ec5a8ac"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Clinical Studies in Adolescents</h2>
<p class="First">In a double-blind, placebo-controlled study, 175 patients (99 adolescent boys and 76 post-menarchal girls) 10 to 17 years of age (mean age 14.1 years) with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (HeFH) were randomized to simvastatin (n = 106) or placebo (n = 67) for 24 weeks (base study). Inclusion in the study required a baseline LDL-C level between 160 and 400 mg/dL and at least one parent with an LDLÂ­C level &gt; 189 mg/dL. The dosage of simvastatin (once daily in the evening) was 10 mg for the first 8 weeks, 20 mg for the second 8 weeks, and 40 mg thereafter. In a 24 week extension, 144 patients elected to continue therapy with simvastatin 40 mg or placebo. </p>
<p>Simvastatin significantly decreased plasma levels of total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span> (see <span class="Bold"><a href="#id_ef810d91-e7ea-47f9-b4b8-9fca47606531">TABLE 8</a></span>). Results from the extension at 48 weeks were comparable to those observed in the base study.</p>
<a name="id_ef810d91-e7ea-47f9-b4b8-9fca47606531"></a><table border="1" width="439">
<caption><span>TABLE 8: Lipid-Lowering Effects of Simvastatin in Adolescent Patients With <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> (Mean Percent Change From Baseline)</span></caption>
<col width="10.9%">
<col width="11.2%">
<col width="6.6%">
<col width="11.6%">
<col width="13.4%">
<col width="11.6%">
<col width="13.4%">
<col width="9.6%">
<col width="11.6%">
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">*</a></dt>
<dd>median percent change</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="middle">Dosage</td>
<td class="Botrule" align="center" valign="middle">Duration</td>
<td class="Botrule" align="center" valign="middle">N</td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">Total-C</td>
<td class="Botrule" align="center" valign="middle">LDL-C</td>
<td class="Botrule" align="center" valign="middle">HDL-C</td>
<td class="Botrule" align="center" valign="middle">TG<a name="footnote-reference-17" href="#footnote-17" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">Placebo</td>
<td align="center" valign="middle">24 Weeks</td>
<td align="center" valign="middle">67</td>
<td align="center" valign="middle">
<p class="First">% Change from Baseline</p>
<p>(95% CI)</p>
</td>
<td align="center" valign="middle">
<p class="First">1.6</p>
<p>(-2.2, 5.3)</p>
</td>
<td align="center" valign="middle">
<p class="First">1.1</p>
<p>(-3.4, 5.5)</p>
</td>
<td align="center" valign="middle">
<p class="First">3.6</p>
<p>(-0.7, 8)</p>
</td>
<td align="center" valign="middle">
<p class="First">-3.2</p>
<p>(-11.8, 5.4)</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">-0.5</p>
<p>(-4.7, 3.6)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">
<p class="First">Mean baseline, mg/dL</p>
<p>(SD)</p>
</td>
<td class="Botrule" align="center" valign="middle">
<p class="First">278.6</p>
<p>(51.8)</p>
</td>
<td class="Botrule" align="center" valign="middle">
<p class="First">211.9</p>
<p>(49)</p>
</td>
<td class="Botrule" align="center" valign="middle">
<p class="First">46.9</p>
<p>(11.9)</p>
</td>
<td class="Botrule" align="center" valign="middle">
<p class="First">90</p>
<p>(50.7)</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">186.3</p>
<p>(38.1)</p>
</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">Simvastatin</td>
<td align="center" valign="middle">24 Weeks</td>
<td align="center" valign="middle">106</td>
<td align="center" valign="middle">
<p class="First">% Change from Baseline</p>
<p>(95% CI)</p>
</td>
<td align="center" valign="middle">
<p class="First">-26.5</p>
<p>(-29.6, -23.3)</p>
</td>
<td align="center" valign="middle">
<p class="First">-36.8</p>
<p>(-40.5, -33)</p>
</td>
<td align="center" valign="middle">
<p class="First">8.3</p>
<p>(4.6, 11.9)</p>
</td>
<td align="center" valign="middle">
<p class="First">-7.9</p>
<p>(-15.8, 0)</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">-32.4</p>
<p>(-35.9, -29)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle">
<p class="First">Mean baseline, mg/dL</p>
<p>(SD)</p>
</td>
<td align="center" valign="middle">
<p class="First">270.2</p>
<p>(44)</p>
</td>
<td align="center" valign="middle">
<p class="First">203.8</p>
<p>(41.5)</p>
</td>
<td align="center" valign="middle">
<p class="First">47.7</p>
<p>(9)</p>
</td>
<td align="center" valign="middle">
<p class="First">78.3</p>
<p>(46)</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">179.9</p>
<p>(33.8)</p>
</td>
</tr>
</tbody>
</table>
<p>After 24 weeks of treatment, the mean achieved LDL-C value was 124.9 mg/dL (range: 64 to 289 mg/dL) in the simvastatin 40 mg group compared to 207.8 mg/dL (range: 128 to 334 mg/dL) in the placebo group.</p>
<p>The safety and efficacy of doses above 40 mg daily have not been studied in children with HeFH. The long-term efficacy of simvastatin therapy in childhood to reduce morbidity and mortality in adulthood has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_a5f8b188-2990-4587-9306-36b2c478a081"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Simvastatin tablets USP are supplied as follows:</p>
<p>5 mg: Light-yellow, round, convex, film-coated tablets, debossed â€œ7152â€? on one side and â€œTVâ€? on the other side. They are supplied in bottles of 3240.</p>
<p><span class="Bold">Storage</span></p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>KEEP THIS AND ALL MEDICATION OUT OF REACH OF CHILDREN.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_0e347208-e4c6-4391-bccd-bce259c35e3e"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised to adhere to their National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program (NCEP)-recommended diet, a regular exercise program, and periodic testing of a fasting lipid panel. </p>
<p><span class="Bold">Patients should be advised about substances they should not take concomitantly with simvastatin [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_a28c33a0-f7fc-4585-88f4-953712bf3017">4</a>) and Warnings and Precautions (<a href="#i4i_section_id_e79cf7aa-0973-4738-b543-b363fe3bdc28">5.1</a>)</span>]. Patients should also be advised to inform other healthcare professionals prescribing a new medication or increasing the dose of an existing medication that they are taking simvastatin tablets. </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_22379454-7d00-4294-8c63-564b94246303"></a><a name="section-15.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span></h2>
<p class="First">All patients starting therapy with simvastatin tablets should be advised of the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and told to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>  particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if these muscle signs or symptoms persist after discontinuing simvastatin tablets. <span class="Bold">Patients using the 80 mg dose should be informed that the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, is increased with use of the 80 mg dose. </span>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, occurring with use of simvastatin tablets is increased when taking certain types of medication or consuming grapefruit juice. Patients should discuss all medication, both prescription and over the counter, with their healthcare professional. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e1fe43ac-ddca-451d-a4fb-0e6d7b3d8223"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Liver Enzymes</h2>
<p class="First">It is recommended that liver function tests be performed before the initiation of simvastatin tablets, and thereafter when clinically indicated. All patients treated with simvastatin tablets should be advised to report promptly any symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_292ef561-07e1-4987-9ea7-6a2fe944ddb5"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Pregnancy </h2>
<p class="First">Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using simvastatin tablets. Discuss future pregnancy plans with your patients, and discuss when to stop taking simvastatin tablets if they are trying to conceive. Patients should be advised that if they become pregnant they should stop taking simvastatin tablets and call their healthcare professional.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dcf4410a-cf4d-47b6-b318-091a3d1cf0c4"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Breastfeeding </h2>
<p class="First">Women who are breastfeeding should not use simvastatin tablets. Patients who have a lipid disorder and are breastfeeding should be advised to discuss the options with their healthcare professional.</p>
<p>Manufactured In Czech Republic By:</p>
<p><span class="Bold">TEVA Czech Industries, s.r.o.</span></p>
<p>Opava-Komarov, Czech Republic</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. Z 11/2012</p>
<p><span class="Bold">Repackaged by:</span><br>KAISER FOUNDATION HOSPITALS
<br>Livermore, CA  94551</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_17d4a45d-7099-48b6-a74d-0b34934b543e"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Simvastatin Tablets USP 5 mg 90s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6985b00-59b5-4ff3-a940-478c616fc227&amp;name=simvastatin-03.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13da5dc0-d884-414a-a10e-cefd97b37469"></a><a name="section-16.1"></a><p></p>
<h2>Simvastatin Tablets USP 5 mg Label Text</h2>
<p class="First"><span class="Bold">NDC </span>0179-<span class="Bold">0128</span>-80</p>
<p><span class="Bold">SIMVASTATIN<br>Tablets USP<br>5 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">3240 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
<p><span class="Bold">Repackaged by:</span><br>KAISER FOUNDATION HOSPITALS
<br>Livermore, CA  94551</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SIMVASTATINÂ 		
					</strong><br><span class="contentTableReg">simvastatin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0179-0128(NDC:0093-7152)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SIMVASTATIN</strong> (SIMVASTATIN) </td>
<td class="formItem">SIMVASTATIN</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASCORBIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (light-yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">7152;TV</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0179-0128-80</td>
<td class="formItem">3240  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076052</td>
<td class="formItem">02/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>KAISER FOUNDATION HOSPITALS
							(053052619)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">KAISER FOUNDATION HOSPITALS</td>
<td class="formItem"></td>
<td class="formItem">053052619</td>
<td class="formItem">repack(0179-0128)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>13b2a26c-df43-4eb1-9983-84de90cccd55</div>
<div>Set id: c6985b00-59b5-4ff3-a940-478c616fc227</div>
<div>Version: 2</div>
<div>Effective Time: 20130208</div>
</div>
</div>Â <div class="DistributorName">KAISER FOUNDATION HOSPITALS</div></p>
</body></html>
